Symbols / DNA
DNA Chart
About
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 536.83M |
| Enterprise Value | 464.58M | Income | -339.55M | Sales | 180.61M |
| Book/sh | 9.85 | Cash/sh | 8.13 | Dividend Yield | — |
| Payout | 0.00% | Employees | 834 | IPO | — |
| P/E | — | Forward P/E | -2.44 | PEG | — |
| P/S | 2.97 | P/B | 0.90 | P/C | — |
| EV/EBITDA | -1.71 | EV/Sales | 2.57 | Quick Ratio | 4.20 |
| Current Ratio | 4.39 | Debt/Eq | 75.54 | LT Debt/Eq | — |
| EPS (ttm) | -6.18 | EPS next Y | -3.63 | EPS Growth | — |
| Revenue Growth | -56.40% | Earnings | 2026-02-26 | ROA | -15.55% |
| ROE | -50.02% | ROIC | — | Gross Margin | 72.71% |
| Oper. Margin | -227.29% | Profit Margin | -188.00% | Shs Outstand | 48.52M |
| Shs Float | 40.19M | Short Float | 14.16% | Short Ratio | 7.81 |
| Short Interest | — | 52W High | 17.58 | 52W Low | 5.00 |
| Beta | 1.56 | Avg Volume | 1.01M | Volume | 547.62K |
| Target Price | $10.00 | Recom | None | Prev Close | $8.86 |
| Price | $8.86 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$8.86
Latest analyst target
3. DCF / Fair value
$-30.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.86
Low
$9.00
High
$12.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-08 | main | TD Cowen | Buy → Buy | $12 |
| 2025-08-25 | main | BTIG | Sell → Sell | $9 |
| 2024-09-20 | main | TD Cowen | Buy → Buy | $10 |
| 2024-08-23 | main | BTIG | Sell → Sell | $7 |
| 2024-07-09 | main | Goldman Sachs | Sell → Sell | $0 |
| 2024-06-26 | main | BTIG | Sell → Sell | $0 |
| 2024-05-15 | down | BTIG | Neutral → Sell | — |
| 2024-05-15 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $1 |
| 2024-05-10 | down | William Blair | Market Perform → Underperform | — |
| 2024-03-01 | main | TD Cowen | Outperform → Outperform | $3 |
| 2024-01-23 | main | Goldman Sachs | Sell → Sell | $1 |
| 2024-01-22 | main | Goldman Sachs | Sell → Sell | $1 |
| 2023-11-15 | down | Raymond James | Outperform → Market Perform | $3 |
| 2023-11-14 | down | Raymond James | Outperform → Market Perform | $3 |
| 2023-11-09 | down | BTIG | Buy → Neutral | — |
| 2023-06-05 | main | Goldman Sachs | Sell → Sell | $1 |
| 2023-06-02 | down | Goldman Sachs | Neutral → Sell | $1 |
| 2023-05-11 | down | William Blair | Outperform → Market Perform | — |
| 2022-11-29 | init | Berenberg | — → Buy | $6 |
| 2022-10-04 | init | Morgan Stanley | — → Equal-Weight | $5 |
News
RSS: Latest DNA news- Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts - Yahoo Finance ue, 17 Feb 2026 23
- GPT-5 lab runs 36,000 experiments, cuts protein costs 40% - Stock Titan hu, 05 Feb 2026 08
- Officials share more about gloves and DNA found during Nancy Guthrie investigation - Scripps News Mon, 23 Feb 2026 20
- $DNA stock is up 7% today. Here's what we see in our data. - Quiver Quantitative Fri, 06 Feb 2026 08
- Best Genomics Stocks of 2026: Are They Right for Your Portfolio? - The Motley Fool hu, 05 Feb 2026 08
- Ginkgo Bioworks Stock: Not There Yet (NYSE:DNA) - Seeking Alpha ue, 11 Nov 2025 08
- “Fair Share” and the Digital Networks Act (DNA): Three Concerns - Internet Society hu, 22 Jan 2026 08
- Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts - Nasdaq hu, 08 Jan 2026 08
- Why Investors Shouldn't Be Surprised By Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 39% Share Price Plunge - simplywall.st Mon, 17 Nov 2025 08
- Ginkgo Bioworks Holdings, Inc. (DNA) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance Fri, 23 Jan 2026 08
- Best Genetic Sequencing Stocks to Buy in 2026 and How to Invest in Them - The Motley Fool hu, 05 Feb 2026 08
- $DNA stock is up 15% today. Here's what we see in our data. - Quiver Quantitative Mon, 29 Sep 2025 07
- Ginkgo Bioworks (NYSE: DNA) lands four-year, up to $47M PNNL automation deal - Stock Titan Fri, 05 Dec 2025 08
- Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance Fri, 25 Jul 2025 07
- Ginkgo Bioworks (NYSE: DNA) to host quarterly results Q&A Nov. 6 at 4:30 p.m. ET - Stock Titan hu, 30 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 972 | 8667.0 | — | Sale at price 8.92 per share. | COEN STEVEN P. | Chief Financial Officer | — | 2026-01-20 00:00:00 | D |
| 1 | 1805 | nan | — | — | COEN STEVEN P. | Chief Financial Officer | — | 2026-01-16 00:00:00 | D |
| 2 | 736 | 6540.0 | — | Sale at price 8.89 per share. | COEN STEVEN P. | Chief Financial Officer | — | 2025-12-15 00:00:00 | D |
| 3 | 1486 | nan | — | — | COEN STEVEN P. | Chief Financial Officer | — | 2025-12-12 00:00:00 | D |
| 4 | 1312 | 17907.0 | — | Sale at price 13.65 per share. | COEN STEVEN P. | Chief Financial Officer | — | 2025-10-17 00:00:00 | D |
| 5 | 2547 | nan | — | — | COEN STEVEN P. | Chief Financial Officer | — | 2025-10-16 00:00:00 | D |
| 6 | 5609 | 84135.0 | — | Sale at price 15.00 per share. | COEN STEVEN P. | Chief Financial Officer | — | 2025-10-01 00:00:00 | D |
| 7 | 20000 | 219800.0 | — | Sale at price 10.92 - 11.06 per share. | HENRY CHRISTIAN O | Director | — | 2025-09-09 00:00:00 | D |
| 8 | 310 | 3843.0 | — | Sale at price 12.40 per share. | COEN STEVEN P. | Chief Financial Officer | — | 2025-08-22 00:00:00 | D |
| 9 | 743 | nan | — | — | COEN STEVEN P. | Chief Financial Officer | — | 2025-08-21 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -102.17K | -14.98K | 733.32K | 70.90K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.01 | 0.00 |
| NormalizedEBITDA | -382.23M | -633.97M | -2.18B | -1.88B |
| TotalUnusualItems | -102.17M | -188.37M | 103.52M | 70.90M |
| TotalUnusualItemsExcludingGoodwill | -102.17M | -188.37M | 103.52M | 70.90M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -547.03M | -892.87M | -2.10B | -1.83B |
| ReconciledDepreciation | 63.02M | 70.51M | 42.55M | 29.08M |
| ReconciledCostOfRevenue | 44.55M | 54.01M | 204.22M | 129.69M |
| EBITDA | -484.39M | -822.34M | -2.08B | -1.81B |
| EBIT | -547.41M | -892.85M | -2.12B | -1.84B |
| NetInterestIncome | 38.52M | 57.12M | 20.16M | -1.54M |
| InterestExpense | 94.00K | 93.00K | 106.00K | 2.37M |
| InterestIncome | 38.61M | 57.22M | 20.26M | 837.00K |
| NormalizedIncome | -444.96M | -704.51M | -2.21B | -1.90B |
| NetIncomeFromContinuingAndDiscontinuedOperation | -547.03M | -892.87M | -2.10B | -1.83B |
| TotalExpenses | 714.77M | 1.02B | 2.69B | 2.14B |
| TotalOperatingIncomeAsReported | -559.76M | -864.41M | -2.21B | -1.83B |
| DilutedAverageShares | 51.89M | 48.61M | 42.00M | 34.01M |
| BasicAverageShares | 51.89M | 48.61M | 41.98M | 34.00M |
| DilutedEPS | -10.54 | -18.37 | -50.00 | -55.60 |
| BasicEPS | -10.54 | -18.37 | -50.00 | -54.00 |
| DilutedNIAvailtoComStockholders | -547.03M | -892.87M | -2.10B | -1.89B |
| NetIncomeCommonStockholders | -547.03M | -892.87M | -2.10B | -1.89B |
| OtherunderPreferredStockDividend | 0.00 | 3.14M | 58.62M | |
| NetIncome | -547.03M | -892.87M | -2.10B | -1.83B |
| MinorityInterests | 0.00 | 0.00 | 1.44M | 6.59M |
| NetIncomeIncludingNoncontrollingInterests | -547.03M | -892.87M | -2.11B | -1.84B |
| NetIncomeContinuousOperations | -547.03M | -892.87M | -2.11B | -1.84B |
| TaxProvision | -479.00K | -71.00K | -15.03M | -1.48M |
| PretaxIncome | -547.51M | -892.94M | -2.12B | -1.84B |
| OtherIncomeExpense | -98.30M | -181.87M | 67.40M | -8.12M |
| OtherNonOperatingIncomeExpenses | 3.87M | 9.14M | 7.63M | -1.73M |
| SpecialIncomeCharges | -79.04M | -138.71M | 31.89M | 23.83M |
| GainOnSaleOfBusiness | -7.01M | -42.50M | 31.89M | 0.00 |
| OtherSpecialCharges | -23.83M | |||
| ImpairmentOfCapitalAssets | 47.86M | 96.21M | 0.00 | 0.00 |
| RestructuringAndMergernAcquisition | 24.17M | 0.00 | 0.00 | |
| EarningsFromEquityInterest | 0.00 | -2.63M | -43.76M | -77.28M |
| GainOnSaleOfSecurity | -23.13M | -49.66M | 71.64M | 47.07M |
| NetNonOperatingInterestIncomeExpense | 38.52M | 57.12M | 20.16M | -1.54M |
| InterestExpenseNonOperating | 94.00K | 93.00K | 106.00K | 2.37M |
| InterestIncomeNonOperating | 38.61M | 57.22M | 20.26M | 837.00K |
| OperatingIncome | -487.73M | -768.20M | -2.21B | -1.83B |
| OperatingExpense | 670.22M | 965.65M | 2.48B | 2.01B |
| ResearchAndDevelopment | 424.06M | 580.62M | 1.05B | 1.15B |
| SellingGeneralAndAdministration | 246.16M | 385.02M | 1.43B | 862.95M |
| GeneralAndAdministrativeExpense | 246.16M | 385.02M | 1.43B | 862.95M |
| OtherGandA | 246.16M | 385.02M | 1.43B | 862.95M |
| GrossProfit | 182.50M | 197.45M | 273.49M | 184.15M |
| CostOfRevenue | 44.55M | 54.01M | 204.22M | 129.69M |
| TotalRevenue | 227.04M | 251.46M | 477.71M | 313.84M |
| OperatingRevenue | 227.04M | 251.46M | 477.71M | 313.84M |
| Line Item | 2023-12-31 | 2021-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 79.60M | ||
| OrdinarySharesNumber | 54.37M | 50.03M | 47.30M | 40.28M |
| ShareIssued | 54.37M | 50.03M | 47.30M | 40.28M |
| TotalDebt | 467.73M | 239.31M | 442.59M | 23.03M |
| TangibleBookValue | 643.55M | 965.17M | 1.57B | 1.46B |
| InvestedCapital | 716.06M | 1.10B | 1.74B | 1.51B |
| WorkingCapital | 495.48M | 837.89M | 1.28B | 1.59B |
| NetTangibleAssets | 643.55M | 965.17M | 1.57B | 1.46B |
| CapitalLeaseObligations | 467.73M | 239.31M | 442.59M | 23.03M |
| CommonStockEquity | 716.06M | 1.10B | 1.74B | 1.51B |
| TotalCapitalization | 716.06M | 1.10B | 1.74B | 1.51B |
| TotalEquityGrossMinorityInterest | 716.06M | 1.10B | 1.74B | 1.57B |
| MinorityInterest | 0.00 | 0.00 | 0.00 | 62.01M |
| StockholdersEquity | 716.06M | 1.10B | 1.74B | 1.51B |
| GainsLossesNotAffectingRetainedEarnings | -1.81M | 1.48M | -2.63M | -1.72M |
| OtherEquityAdjustments | -1.81M | 1.48M | -2.63M | -1.72M |
| RetainedEarnings | -5.84B | -5.29B | -4.40B | -2.30B |
| AdditionalPaidInCapital | 6.56B | 6.39B | 6.14B | 3.80B |
| CapitalStock | 5.00K | 5.00K | 190.00K | 161.00K |
| CommonStock | 5.00K | 5.00K | 190.00K | 161.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 661.39M | 568.19M | 803.04M | 503.61M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 554.12M | 404.33M | 630.08M | 368.85M |
| OtherNonCurrentLiabilities | 16.58M | 24.43M | 31.19M | 35.99M |
| DerivativeProductLiabilities | 5.70M | 10.87M | 135.84M | |
| NonCurrentDeferredLiabilities | 98.78M | 158.06M | 174.77M | 174.74M |
| NonCurrentDeferredRevenue | 98.78M | 158.06M | 174.77M | 155.99M |
| LongTermDebtAndCapitalLeaseObligation | 438.77M | 221.84M | 413.26M | 22.28M |
| LongTermCapitalLeaseObligation | 438.77M | 221.84M | 413.26M | 22.28M |
| CurrentLiabilities | 107.27M | 163.86M | 172.96M | 134.76M |
| OtherCurrentLiabilities | 14.34M | 38.70M | 33.06M | 34.06M |
| CurrentDeferredLiabilities | 30.60M | 48.49M | 47.82M | 33.24M |
| CurrentDeferredRevenue | 30.60M | 48.49M | 47.82M | 33.24M |
| CurrentDebtAndCapitalLeaseObligation | 28.96M | 17.47M | 29.33M | 747.00K |
| CurrentCapitalLeaseObligation | 28.96M | 17.47M | 29.33M | 747.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 12.28M | 15.68M | 19.44M | 6.26M |
| PayablesAndAccruedExpenses | 21.08M | 43.51M | 43.31M | 60.46M |
| CurrentAccruedExpenses | 6.91M | 34.19M | 32.86M | 52.27M |
| Payables | 14.17M | 9.32M | 10.45M | 8.19M |
| AccountsPayable | 14.17M | 9.32M | 10.45M | 8.19M |
| TotalAssets | 1.38B | 1.67B | 2.54B | 2.07B |
| TotalNonCurrentAssets | 774.71M | 663.59M | 1.09B | 347.94M |
| OtherNonCurrentAssets | 55.34M | 58.05M | 47.81M | 43.99M |
| NonCurrentNoteReceivables | 13.60M | 37.66M | 0.00 | |
| FinancialAssets | 238.00K | 654.00K | 1.94M | |
| InvestmentsAndAdvances | 48.47M | 77.91M | 111.79M | 115.23M |
| OtherInvestments | 16.69M | 23.90M | 22.11M | 102.04M |
| InvestmentinFinancialAssets | 31.78M | 54.01M | 88.14M | |
| AvailableForSaleSecurities | 31.78M | 54.01M | 88.14M | |
| LongTermEquityInvestment | 0.00 | 1.54M | 13.19M | |
| GoodwillAndOtherIntangibleAssets | 72.51M | 131.98M | 171.25M | 42.95M |
| OtherIntangibleAssets | 72.51M | 82.74M | 111.04M | 21.64M |
| Goodwill | 0.00 | 49.24M | 60.21M | 21.31M |
| NetPPE | 598.15M | 394.99M | 718.79M | 145.77M |
| AccumulatedDepreciation | -160.87M | -120.72M | -92.76M | -61.05M |
| GrossPPE | 759.03M | 515.71M | 811.55M | 206.82M |
| Leases | 135.96M | 71.56M | 125.31M | 55.03M |
| ConstructionInProgress | 1.98M | 15.83M | 23.43M | 10.28M |
| OtherProperties | 545.32M | 353.99M | 587.31M | 113.96M |
| MachineryFurnitureEquipment | 21.44M | 21.24M | 23.43M | 14.79M |
| BuildingsAndImprovements | 48.26M | 47.03M | 46.02M | 12.76M |
| LandAndImprovements | 6.06M | 6.06M | 6.06M | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 602.74M | 1.00B | 1.45B | 1.72B |
| OtherCurrentAssets | 18.73M | 39.78M | 487.00K | 698.00K |
| RestrictedCash | 4.79M | 8.22M | 0.00 | |
| PrepaidAssets | 20.74M | 37.19M | 19.08M | |
| Inventory | 46.00K | 4.36M | 3.36M | |
| InventoriesAdjustmentsAllowances | -3.78M | -16.00K | ||
| FinishedGoods | 6.56M | 3.26M | ||
| WorkInProcess | 0.00 | 50.00K | ||
| RawMaterials | 1.59M | 64.00K | ||
| Receivables | 22.44M | 17.90M | 84.03M | 149.90M |
| OtherReceivables | 1.55M | 1.56M | 2.20M | |
| DuefromRelatedPartiesCurrent | 586.00K | 742.00K | 1.56M | 4.60M |
| NotesReceivable | 12.29M | 0.00 | 11.56M | |
| LoansReceivable | 11.56M | |||
| AccountsReceivable | 21.86M | 17.16M | 82.47M | 131.54M |
| AllowanceForDoubtfulAccountsReceivable | -1.00M | -1.10M | ||
| GrossAccountsReceivable | 18.90M | 83.56M | ||
| CashCashEquivalentsAndShortTermInvestments | 561.57M | 944.07M | 1.32B | 1.55B |
| CashAndCashEquivalents | 561.57M | 944.07M | 1.32B | 1.55B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -382.13M | -336.30M | -304.47M | -310.34M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -25.00M | |
| RepaymentOfDebt | -897.00K | -1.29M | -1.24M | -1.12M |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 99.30M | 0.00 |
| CapitalExpenditure | -62.54M | -40.80M | -52.27M | -56.52M |
| InterestPaidSupplementalData | 32.00K | 83.00K | 92.00K | 2.37M |
| IncomeTaxPaidSupplementalData | 894.00K | 670.00K | 0.00 | 61.00K |
| EndCashPosition | 605.74M | 989.58M | 1.37B | 1.59B |
| BeginningCashPosition | 989.58M | 1.37B | 1.59B | 385.88M |
| EffectOfExchangeRateChanges | -281.00K | -588.00K | 908.00K | -19.00K |
| ChangesInCash | -383.56M | -379.41M | -224.25M | 1.21B |
| FinancingCashFlow | -1.74M | -3.22M | 95.34M | 1.53B |
| CashFlowFromContinuingFinancingActivities | -1.74M | -3.22M | 95.34M | 1.53B |
| NetOtherFinancingCharges | -926.00K | -2.01M | -2.97M | 1.56B |
| ProceedsFromStockOptionExercised | 84.00K | 93.00K | 240.00K | 167.00K |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 0.00 | 99.30M | -25.00M |
| CommonStockPayments | 0.00 | 0.00 | -25.00M | |
| CommonStockIssuance | 0.00 | 0.00 | 99.30M | 0.00 |
| NetIssuancePaymentsOfDebt | -897.00K | -1.29M | -1.24M | -1.12M |
| NetLongTermDebtIssuance | -897.00K | -1.29M | -1.24M | -1.12M |
| LongTermDebtPayments | -897.00K | -1.29M | -1.24M | -1.12M |
| InvestingCashFlow | -62.24M | -80.69M | -67.39M | -73.26M |
| CashFlowFromContinuingInvestingActivities | -62.24M | -80.69M | -67.39M | -73.26M |
| NetOtherInvestingChanges | 538.00K | -1.34M | -38.08M | 304.00K |
| NetInvestmentPurchaseAndSale | 4.52M | 0.00 | -3.69M | -5.00M |
| SaleOfInvestment | 4.52M | 0.00 | 0.00 | |
| PurchaseOfInvestment | 0.00 | 0.00 | -3.69M | -5.00M |
| NetBusinessPurchaseAndSale | -5.40M | -42.98M | 26.65M | -12.04M |
| SaleOfBusiness | 82.37M | |||
| PurchaseOfBusiness | -5.40M | -42.98M | -55.72M | -12.04M |
| NetPPEPurchaseAndSale | -61.89M | -36.37M | -52.27M | -56.52M |
| SaleOfPPE | 648.00K | 4.43M | 0.00 | 0.00 |
| PurchaseOfPPE | -62.54M | -40.80M | -52.27M | -56.52M |
| OperatingCashFlow | -319.58M | -295.50M | -252.20M | -253.82M |
| CashFlowFromContinuingOperatingActivities | -319.58M | -295.50M | -252.20M | -253.82M |
| ChangeInWorkingCapital | -89.67M | 29.84M | -37.01M | -61.54M |
| ChangeInOtherWorkingCapital | -68.64M | -35.92M | -36.42M | -4.47M |
| ChangeInOtherCurrentLiabilities | -12.79M | -22.35M | -10.76M | 18.62M |
| ChangeInOtherCurrentAssets | 22.07M | 11.85M | 14.15M | -539.00K |
| ChangeInPayablesAndAccruedExpense | -35.67M | 15.72M | -50.48M | 42.55M |
| ChangeInAccruedExpense | -40.44M | 16.90M | -39.64M | 44.80M |
| ChangeInPayable | 4.77M | -1.18M | -10.84M | -2.25M |
| ChangeInAccountPayable | 4.77M | -1.18M | -10.84M | -2.25M |
| ChangeInPrepaidAssets | 10.09M | 10.47M | -8.52M | -3.61M |
| ChangeInInventory | 164.00K | -626.00K | ||
| ChangeInReceivables | -4.72M | 50.07M | 55.02M | -114.09M |
| ChangesInAccountReceivables | -4.72M | 50.07M | 55.02M | -114.09M |
| OtherNonCashItems | 53.23M | 50.90M | -10.73M | -20.95M |
| StockBasedCompensation | 112.34M | 229.88M | 1.93B | 1.61B |
| AssetImpairmentCharge | 58.48M | 121.40M | 0.00 | 0.00 |
| DeferredTax | -936.00K | -801.00K | -14.61M | 0.00 |
| DeferredIncomeTax | -936.00K | -801.00K | -14.61M | 0.00 |
| DepreciationAmortizationDepletion | 63.02M | 70.51M | 42.55M | 29.08M |
| DepreciationAndAmortization | 63.02M | 70.51M | 42.55M | 29.08M |
| Depreciation | 71.55M | 44.42M | 29.08M | |
| OperatingGainsLosses | 30.98M | 95.64M | -56.67M | 30.21M |
| EarningsLossesFromEquityInvestments | 0.00 | 2.63M | 43.76M | 77.28M |
| GainLossOnInvestmentSecurities | 23.13M | 49.66M | -71.64M | -47.07M |
| GainLossOnSaleOfPPE | 844.00K | 842.00K | 3.09M | 0.00 |
| GainLossOnSaleOfBusiness | 7.01M | 42.50M | -31.89M | 0.00 |
| NetIncomeFromContinuingOperations | -547.03M | -892.87M | -2.11B | -1.84B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for DNA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|